A recent study reported that sustained sorafenib treatment leads to decreased microvessel density and increased HIF-1α protein levels and transcriptional activity in HCC [20], consequently leading to sorafenib resistance. This evidence concerns the gene HIF1A and hepatocellular carcinoma.